Abstract: TH-PO0567
Global, Regional, and National Macroeconomic Burden of CKD in 2023
Session Information
- CKD: From Global Burden to Precision Care - Epidemiology, Demographics, Geographies, and Risk Factors
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2201 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Seth, Sukriti, University of Central Florida College of Medicine/HCA Healthcare GME Consortium,, Ocala,, Florida, United States
- Kodali, Naga Anvesh, University of Central Florida College of Medicine/HCA Healthcare GME Consortium,, Ocala,, Florida, United States
- Desai, Hardik, AB Plus Multispecialty Hospital, Ahmedabad, Gujarat, India
- Mitra, Chandan, University of Central Florida College of Medicine/HCA Healthcare GME Consortium,, Ocala,, Florida, United States
Background
Chronic kidney disease (CKD) is a rising contributor to non-communicable disease burden, yet standardized global estimates of its macroeconomic consequences remain absent. Quantifying these losses can inform resource allocation for prevention, dialysis access, and transplantation.
Methods
CKD disability-adjusted life-year (DALY) data for 2023 were obtained from the Global Burden of Disease study for 188 countries. Gross domestic product (GDP), purchasing power parity (PPP)-adjusted GDP, GDP per capita, and population were obtained from the World Bank. Macroeconomic losses were estimated using the value of lost welfare (VLW) framework, combining DALYs with country-specific value of statistical life calibrated using a United States anchor and an income elasticity of 1.0 (sensitivities 0.55 and 1.5). Results were aggregated to 7 GBD super-regions and expressed in 2023 international US$ adjusted for PPP.
Results
Global CKD VLW in 2023 was $933.8 billion, equal to 0.51% of global GDP (PPP). VLW/GDP was highest in Latin America and the Caribbean (0.76%; $101.9B), followed by the high-income super-region (0.61%; $429.8B), North Africa and Middle East (0.55%; $78.2B), and sub-Saharan Africa (0.54%; $35.1B). The United States ($229.3B; 0.83% GDP), China ($106.5B), India ($46.4B), Japan ($42.8B), and Mexico ($39.7B) had the largest absolute losses. Mauritius, El Salvador, Puerto Rico, Trinidad and Tobago, and Guyana had the highest VLW/GDP (>1.6%).
Conclusion
The global macroeconomic cost of CKD approaches one trillion 2023 international US$, with disproportionate relative impact in Latin America, the Caribbean, and Mesoamerican CKD-of-unknown-aetiology corridors. These data support increased investment in CKD prevention, early detection, and renal replacement therapy access.